Zydus Lifesciences (NSEI:ZYDUSLIFE) - Aandelenkoers, Nieuws & Analyse

ZYDUSLIFE Overzicht aandelen

Zydus Lifesciences Limited houdt zich bezig met onderzoek, ontwikkeling, productie, marketing, distributie en verkoop van farmaceutische producten in India, de Verenigde Staten en internationaal.

Over het bedrijf

ZYDUSLIFE fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	0/6
Prestaties in het verleden	5/6
Financiële gezondheid	6/6
Dividenden	4/6

Beloningen

De koers-winstverhouding ( 23.5 x) ligt onder de Indian markt ( 33.5 x)

De winst groeide het afgelopen jaar met 65%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Analisten zijn het erover eens dat de aandelenkoers met 20.1% zal stijgen

Risicoanalyse

Onstabiel dividend track record

Zydus Lifesciences Limited Concurrenten

Lupin

BSE:500257

₹962.8b

Torrent Pharmaceuticals

BSE:500420

₹1.1t

Dr. Reddy's Laboratories

BSE:500124

₹1.1t

Cipla

NSEI:CIPLA

₹1.3t

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Zydus Lifesciences
Historische aandelenkoersen
Huidige aandelenkoers	₹973.25
52 Week Hoogtepunt	₹1,324.30
52 Week Laag	₹606.05
Bèta	0.42
11 maand verandering	-7.72%
3 maanden verandering	-25.19%
1 Jaar Verandering	58.91%
33 jaar verandering	97.84%
5 jaar verandering	315.47%
Verandering sinds IPO	11,116.98%

Recent nieuws en updates

Recent updates

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Sep 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Aug 30

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 14

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Aug 03

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Jul 19

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 05

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Feb 28

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Feb 12

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Dec 27

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Dec 06

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Aug 23

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

Jul 17

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Jul 15

Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's

Jun 24

Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00

Jun 10

Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00

May 21

Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly

Feb 15

We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt

Nov 13

Rendement voor aandeelhouders

	ZYDUSLIFE	IN Pharmaceuticals	IN Markt
7D	-2.8%	3.0%	1.6%
1Y	58.9%	54.1%	36.9%

Rendement versus industrie: ZYDUSLIFE overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 54.1 % opleverde.

Rendement versus markt: ZYDUSLIFE overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 36.9 %.

Prijsvolatiliteit

Is ZYDUSLIFE's price volatile compared to industry and market?
ZYDUSLIFE volatility
ZYDUSLIFE Average Weekly Movement	3.6%
Pharmaceuticals Industry Average Movement	6.3%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.3%
10% least volatile stocks in IN Market	4.0%

Stabiele aandelenkoers: ZYDUSLIFE heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van ZYDUSLIFE is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1952	26,921	Sharvil Patel	zyduslife.com

Zydus Lifesciences Limited houdt zich bezig met onderzoek, ontwikkeling, productie, marketing, distributie en verkoop van farmaceutische producten in India, de Verenigde Staten en internationaal. Het is actief in twee segmenten: Farmaceutische Producten en Consumentenproducten. Het biedt afgewerkte doseringsformuleringen voor mensen, zoals generieke geneesmiddelen; merkgenerieke geneesmiddelen; speciale formuleringen, waaronder biosimilars en vaccins; actieve farmaceutische ingrediënten; welzijnsproducten voor de consument; producten voor diergezondheid; en producten in de therapeutische gebieden pijnbestrijding, neurologie, stofwisselingsstoornissen en leverziekten.

Zydus Lifesciences Limited Samenvatting

Hoe verhouden de winst en inkomsten van Zydus Lifesciences zich tot de beurswaarde?
ZYDUSLIFE fundamentele statistieken
Marktkapitalisatie	₹979.32b
Inkomsten(TTM)	₹41.69b
Inkomsten(TTM)	₹206.15b

23.5x

Koers/Winstverhouding

4.8x

P/S-verhouding

Is ZYDUSLIFE overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ZYDUSLIFE resultatenrekening (TTM)
Inkomsten	₹206.15b
Kosten van inkomsten	₹63.05b
Brutowinst	₹143.10b
Overige uitgaven	₹101.41b
Inkomsten	₹41.69b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 12, 2024

Winst per aandeel (EPS)	41.43
Brutomarge	69.41%
Nettowinstmarge	20.22%
Schuld/Eigen Vermogen Verhouding	3.7%

Hoe presteerde ZYDUSLIFE op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.3%

Huidig dividendrendement

8%

Uitbetalingsratio

ZYDUSLIFE Overzicht aandelen

Beloningen

Risicoanalyse

Zydus Lifesciences Limited Concurrenten

BSE:500257

₹962.8b

BSE:500420

₹1.1t

BSE:500124

₹1.1t

NSEI:CIPLA

₹1.3t

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Zydus Lifesciences Limited to Report Q2, 2025 Results on Nov 12, 2024

Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv

Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg

Zydus Lifesciences Limited and ICMR Initiate A Phase 2 Proof-Of-Concept Trial of Desidustat in Patients with Sickle Cell Disease

Zydus Lifesciences Limited Receives Final Approval from USFDA for Paliperidone Extended-Release Tablets

Zydus Receives Tentative Approval from USFDA for Enzalutamide Tablets, 40 Mg and 80 Mg

Recent updates

Zydus Lifesciences Limited to Report Q2, 2025 Results on Nov 12, 2024

Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv

Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg

Zydus Lifesciences Limited and ICMR Initiate A Phase 2 Proof-Of-Concept Trial of Desidustat in Patients with Sickle Cell Disease

Zydus Lifesciences Limited Receives Final Approval from USFDA for Paliperidone Extended-Release Tablets

Zydus Receives Tentative Approval from USFDA for Enzalutamide Tablets, 40 Mg and 80 Mg

Here's Why We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Is Well Worth Watching

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) Business And Shares Still Trailing The Market

Zydus Lifesciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target increased by 8.1% to ₹1,145

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2024

Zydus Lifesciences Limited's (NSE:ZYDUSLIFE) CEO Compensation Is Looking A Bit Stretched At The Moment

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration to Market Valsartan Tablets USP, 40 Mg, 80 Mg, 160 Mg and 320 Mg (USRLD: Diovan® Tablets)

Zydus Lifesciences Limited Receives Approval from COFEPRIS of Mexico to Market Bhava

Upcoming dividend of ₹3.00 per share

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences Limited to Report Q1, 2025 Results on Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year

Zydus Receives Tentative Approval from Usfda for Azilsartan Medoxomil Tablets, 40 Mg and 80 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences (NSE:ZYDUSLIFE) Will Pay A Smaller Dividend Than Last Year

Consensus EPS estimates increase by 10%

Dividend reduced to ₹3.00

Price target increased by 9.2% to ₹925

Zydus Lifesciences Limited, Annual General Meeting, Aug 09, 2024

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Lifesciences Limited Proposes Final Dividend for the Financial Year Ended on March 31, 2024, Payable on or After August 13, 2024

Zydus Lifesciences Limited Announces Completion of Enrolment for EPICS IIITM Phase 2B/3 Trial Evaluating Saroglitazar Mg in Treatment of Primary Biliary Cholangitis

Zydus Lifesciences Limited Receives Final Approval from USFDA for Dapsone Gel, 7.5%

Bayer Pharmaceuticals Pvt. Ltd. agreed to acquire the remaining 24.99998% stake in Bayer Zydus Pharma Private Limited for INR 2.82 billion.

Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S

Insider recently sold ₹833k worth of stock

Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?

Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%

Price target increased by 9.3% to ₹753

Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zydus Receives Tentative Approval from the USFDA for Dexamethasone Tablets USP, 1 mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration to Manufacture and Market Dexamethasone Tablets USP, 2 Mg

Zydus Lifesciences Launches RexigoTM, the Oral Once-A-Day Pill for Advanced Prostate Cancer Patients in India

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Gabapentin Tablets (Once-Daily), 300 Mg and 600 Mg

Zydus Lifesciences Limited Receives Final Approvals from the United States Food and Drug Administration for Pimavanserin Capsules, 34 Mg and Pimavanserin Tablets,10 Mg

Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt

Zydus Lifesciences Limited Zydus Receives Approval from USFDA to Initiate Phase II Clinical Trial of ZYIL1 in Patients with Parkinson's Disease

Zydus Lifesciences Limited Receives Final Approval from the USFDA for Cyclophosphamide Capsules USP, 25 Mg and 50 Mg

Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Zydus Lifesciences Initiates Phase II Clinical Trial of ZYIL1

Zydus Lifesciences Limited Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus

Zydus Lifesciences Limited Appoints Mr. Punit Patel as President and CEO to Lead Its Business Operations in North America

Zydus Receives Final Approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Zydus Receives Final Approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 Mcg/35 Mcg Per Day

Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Zinc Sulfate Injection USP, 10 mg/10 ml (3 mg/L) Pharmacy Bulk Package Vials

With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case

Consensus EPS estimates increase by 12%

Price target increased by 14% to ₹627

Zydus Lifesciences Limited Approves Final Dividend for the Financial Year Ended on March 31, 2023